Systemic Juvenile Idiopathic Arthritis (SJIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Juvenile idiopathic arthritis (JIA) is a diverse subset of idiopathic inflammatory arthritis that affects children under 16 and lasts for six weeks or more. Seven JIA categories exist oligoarthritis, systemic arthritis, psoriatic arthritis, enthesitis-related arthritis, rheumatoid factor (RF) positive polyarthritis, RF negative polyarthritis, and undifferentiated arthritis. It's yet unknown what causes or triggers persistent arthritis in JIA. It is hypothetical that a genetically sensitive individual will experience aberrant immune responses due to combinations of environmental factors. Breastfeeding and having siblings in the same home are potential protective factors, while other environmental factors, including antibiotic exposure and C-section deliveries, are potential dangers. Microorganisms such as enteric bacteria, Epstein-Barr virus, Parvovirus B19, Chlamydophila pneumoniae, and streptococcal infections still have unclear significance. Most JIA subtypes share the characteristic of an imbalance in regulatory T cells, Th1 (IFN-gamma secreting T cells), and Th17 (interleukin -17 secreting T cells) of adaptive immunity. In oligoarthritis, polyarthritis, and psoriatic arthritis, proinflammatory cytokines and matrix metalloproteinases are induced by IL-17, which results in joint destruction. A key cytokine in ERA, IL-23, promotes inflammation via IL-17 and tumor necrosis factor (TNF) and promotes the growth of new bone via IL-22. Imaging helps to assess joint degeneration, reduce the differential diagnosis, and increase the certainty of a JIA diagnosis. Anti-inflammatory and immunomodulatory medications, physical therapy, and eventually surgery, nutritional support, and psychosocial support may be required for the treatment of juvenile idiopathic arthritis (JIA). For all subtypes, nonsteroidal anti-inflammatory medications (NSAIDs) are the cornerstone of the first line of treatment for symptoms.

Thelansis’s “Systemic Juvenile Idiopathic Arthritis (SJIA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Juvenile Idiopathic Arthritis (SJIA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Systemic Juvenile Idiopathic Arthritis (SJIA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Systemic Juvenile Idiopathic Arthritis (SJIA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Systemic Juvenile Idiopathic Arthritis (SJIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033